Asterias Biotherapeutics (AST) Stock Price, News & Analysis

Company Overview

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.

Key Stats

• Today's Range: $0.0020 to $0.0020
• 50-Day Range: N/A
• 52-Week Range: $0.51 to $2.05
• Volume: 1,000 shs
• Average Volume: 136,653 shs
• Market Capitalization: $111,318.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AST Stock Analysis - Frequently Asked Questions

How were Asterias Biotherapeutics' earnings last quarter?

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) issued its earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to analyst estimates of $2.81 million.

How do I buy shares of Asterias Biotherapeutics?

Shares of AST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Asterias Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Asterias Biotherapeutics investors own include Zynerba Pharmaceuticals (ZYNE), CorMedix (CRMD), Synergy Pharmaceuticals (SGYP), 22nd Century Group (XXII), Amarin (AMRN), Gilead Sciences (GILD) and Progenics Pharmaceuticals (PGNX).

Company Calendar

• Last Earnings: 3/28/2017
• Today: 1/15/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:AST
• Previous Symbol: NYSEMKT:AST
• CUSIP: N/A
• CIK: N/A
• Web: asteriasbiotherapeutics.com
• Phone: +1-510-4563805
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,659,000
• Free Float: N/A
• Market Cap: $111,318.00
• Optionable: Not Optionable
• Beta: N/A